AR054441A1 - Derivados de aminoacidos - Google Patents

Derivados de aminoacidos

Info

Publication number
AR054441A1
AR054441A1 ARP060101665A ARP060101665A AR054441A1 AR 054441 A1 AR054441 A1 AR 054441A1 AR P060101665 A ARP060101665 A AR P060101665A AR P060101665 A ARP060101665 A AR P060101665A AR 054441 A1 AR054441 A1 AR 054441A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
aryl
oxymethyl
amino
Prior art date
Application number
ARP060101665A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36677128&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054441(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of AR054441A1 publication Critical patent/AR054441A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP060101665A 2005-04-28 2006-04-26 Derivados de aminoacidos AR054441A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67602505P 2005-04-28 2005-04-28

Publications (1)

Publication Number Publication Date
AR054441A1 true AR054441A1 (es) 2007-06-27

Family

ID=36677128

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101665A AR054441A1 (es) 2005-04-28 2006-04-26 Derivados de aminoacidos

Country Status (26)

Country Link
US (1) US7612226B2 (https=)
EP (1) EP1879567A1 (https=)
JP (2) JP4173909B1 (https=)
KR (1) KR100925900B1 (https=)
CN (1) CN101166524B (https=)
AP (1) AP2007004161A0 (https=)
AR (1) AR054441A1 (https=)
AU (1) AU2006238933B2 (https=)
BR (1) BRPI0609879A2 (https=)
CA (1) CA2606353C (https=)
CR (1) CR9472A (https=)
DO (1) DOP2006000095A (https=)
EA (1) EA200701852A1 (https=)
GT (1) GT200600178A (https=)
IL (1) IL185790A0 (https=)
MA (1) MA29408B1 (https=)
MX (1) MX2007010978A (https=)
NL (1) NL1031705C2 (https=)
NO (1) NO20076000L (https=)
PE (1) PE20061435A1 (https=)
SV (1) SV2008002512A (https=)
TN (1) TNSN07400A1 (https=)
TW (1) TW200719889A (https=)
UY (1) UY29498A1 (https=)
WO (1) WO2006114707A1 (https=)
ZA (1) ZA200707678B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
BRPI0609879A2 (pt) * 2005-04-28 2010-05-11 Pfizer Ltd derivados de aminoácidos
US20090227680A1 (en) * 2005-11-17 2009-09-10 Pfizer, Inc. Amino Acid Derivatives
CA2664251A1 (en) * 2006-09-12 2008-03-20 Cephalin Pharmaceuticals Inc. Isovaline for treatment of pain
CN101195583B (zh) * 2006-12-04 2012-07-04 四川抗菌素工业研究所有限公司 一种光学纯米那普仑及其盐的制备方法
KR101822319B1 (ko) * 2008-09-09 2018-01-25 에프. 호프만-라 로슈 아게 아실 설폰아미드의 다형체
JP2012176902A (ja) * 2011-02-25 2012-09-13 Tosoh F-Tech Inc 新規な光学活性含フッ素化合物、その製造方法及びそれを用いた光学活性３，３，３−トリフルオロアラニンの製造方法
AT514349B1 (de) * 2013-06-12 2018-05-15 Red Bull Gmbh Alpha-alkylierte Aminosäuren (AAAAs)

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB504209A (en) 1937-12-14 1939-04-21 Pirelli General Cable Works Improvements in or relating to electric cables
BR6239521D0 (pt) * 1961-08-09 1973-06-14 Merck & Co Inc Processo de preparacao de novos amino acidos
FR2586562B1 (fr) 1985-09-02 1989-03-10 Inst Nat Sante Rech Med Composition pharmaceutique contenant de l'a-methylhistamine
DE3811256A1 (de) 1988-04-02 1989-10-19 Hoechst Ag (alpha)-trifluormethylaminosaeure-derivate, verfahren zur herstellung von (alpha)-trifluormethylaminosaeure-derivaten und ihre verwendung als arzneimittel
WO1991001724A1 (en) 1989-07-27 1991-02-21 G.D. Searle & Co. Renal-selective prodrugs for the treatment of hypertension
FR2681067B1 (fr) * 1991-09-10 1993-12-17 Elf Sanofi Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
JPH042899A (ja) 1990-04-16 1992-01-07 Arakawa Chem Ind Co Ltd 紙用サイズ剤および該サイズ剤を用いる紙サイジング方法
FR2661909B1 (fr) 1990-05-09 1997-08-14 Inst Nat Sante Rech Med Nouveaux composes agonistes du recepteur h3 de l'histamine a usage therapeutique, compositions pharmaceutiques agissant comme agonistes dudit recepteur et procede de preparation.
JPH051002A (ja) 1991-02-15 1993-01-08 Nikko Kyodo Co Ltd α−アミノ酸の製造方法
CA2068038A1 (en) 1991-05-08 1992-11-09 Christopher Yee Enzymatic resolution of .alpha.-tertiary carboxylic acid esters
US5993775A (en) 1991-11-27 1999-11-30 Diatide, Inc. Radioactively labeled peptides comprising a single thiol moiety
GB9200210D0 (en) 1992-01-07 1992-02-26 British Bio Technology Compounds
US5786373A (en) 1992-10-14 1998-07-28 Merck & Co., Inc. Fibrinogen receptor antagonists
US5362747A (en) 1992-11-25 1994-11-08 Abbott Laboratories 2-nitroaryl and 2-cyanoaryl compounds as regulators of nitric oxide synthase
GB9325368D0 (en) 1993-12-10 1994-02-16 Univ Bristol Organic compounds
GB9325360D0 (en) 1993-12-10 1994-02-16 Univ Bristol Organic compounds
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
DE19533617A1 (de) 1995-09-11 1997-03-13 Degussa Neues Verfahren zur Herstellung von optisch aktiven alpha-Aminosäuren und alpha-Aminosäure-Derivaten
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
WO1998014208A1 (en) 1996-09-30 1998-04-09 President And Fellows Of Harvard College Reactive ligands and covalent ligand-protein complexes
US5962523A (en) 1996-10-25 1999-10-05 Discovery Laboratories, Inc. Methods of using butyric acid derivatives to protect against hair loss
JPH10333511A (ja) 1997-05-30 1998-12-18 Ricoh Co Ltd 画像除去促進液、該画像除去促進液を用いた被記録材の再生方法及び再生装置
JP4205191B2 (ja) 1997-12-26 2009-01-07 ダイセル化学工業株式会社 α−アミノニトリル誘導体及びα−アミノ酸の製造方法
CN1235559C (zh) 1998-03-11 2006-01-11 株式会社创研 皮肤水分保持能力的改善剂
WO1999054280A1 (en) * 1998-04-17 1999-10-28 Kenneth Curry Cubane derivatives as metabotropic glutamate receptor antagonists and process for their preparation
CZ20011831A3 (cs) 1998-12-18 2001-10-17 Novo Nordisk A/S Kondenzované 1,2,4-thiadiazinové deriváty, jejich příprava a pouľití
JP2002533318A (ja) 1998-12-22 2002-10-08 ニューロサーチ、アクティーゼルスカブ イオンチャネル調節剤
FR2788271B1 (fr) 1999-01-07 2001-02-09 Rhone Poulenc Agrochimie Nouveau procede de preparation d'aminoacides chiraux
ATE294155T1 (de) 1999-01-22 2005-05-15 Pharmacore Inc Eine methode zur herstellung von verbindungen der formel 1 und derivaten
CN1343219A (zh) 1999-01-28 2002-04-03 中外制药株式会社 取代的苯乙基胺衍生物
FR2791982B1 (fr) 1999-04-06 2002-12-27 Inst Nat Sante Rech Med Inhibiteurs de lta4 hydrolase et leurs applications therapeutiques.
WO2001009117A1 (en) 1999-07-29 2001-02-08 Allellix Neuroscience Inc. Tricyclic compounds as glycine transport inhibitors
FR2796943A1 (fr) 1999-07-30 2001-02-02 Aventis Pharma Sa Derives de benzoxazinnes, leur procede de preparation et leur utilisation en therapeutique
EP1210933A4 (en) 1999-09-07 2003-01-22 Soken Kk ACTIVE SUBSTANCES FOR NORMALIZING THE SKIN CONDITION
WO2001017944A1 (en) 1999-09-07 2001-03-15 Mitsubishi Rayon Co., Ltd. Process for producing optically active aminoalcohol
JP2001081013A (ja) 1999-09-10 2001-03-27 Soken Kk 毛髪健全化剤
US7300775B2 (en) 1999-12-29 2007-11-27 Verenium Corporation Methods for producing α-substituted carboxylic acids using nitrilases and strecker reagents
US6656958B2 (en) 2000-02-02 2003-12-02 Abbott Laboratories Substituted pyridine compounds useful for controlling chemical synaptic transmission
DE10121028A1 (de) 2000-05-05 2002-01-31 Basf Ag Verfahren zur Herstellung von Aldehyden
DE10121026A1 (de) 2000-05-05 2002-02-07 Basf Ag Verfahren zur Herstellung von Aldehyden
EP1300392B1 (en) 2000-05-18 2012-09-05 Mitsubishi Rayon Co., Ltd. Process for producing optically active alpha-amino acid and optically active alpha-amino acid amide
WO2003011799A1 (en) 2000-07-31 2003-02-13 Brandeis University Kinetic resolutions of chirat 3- and 3-substituted carboxylic acids
DE10048715A1 (de) * 2000-09-30 2004-05-19 Grünenthal GmbH Verwendung von Aminosäure zur Behandlung von Schmerz
AUPR406901A0 (en) 2001-03-29 2001-04-26 La Trobe University Insecticide and method of controlling insects
JP4715058B2 (ja) 2001-08-02 2011-07-06 Ｊｓｒ株式会社 感放射性樹脂組成物
JP2003221328A (ja) 2002-01-29 2003-08-05 Soken Kk 皮膚健全化剤
US7002036B2 (en) 2002-05-15 2006-02-21 Genzyme Corporation Synthesis of 2-alkyl amino acids
US20060014805A1 (en) 2002-08-01 2006-01-19 Markus Kordes Pesticidal fluoroalkene derivatives
US20060025471A1 (en) * 2002-09-13 2006-02-02 Kenneth Curry Xanthenyl cubane analogs with activity at the metabotropic glutamate receptors
AU2003289242A1 (en) 2003-01-10 2004-08-10 Kaneka Corporation PROCESS FOR PRODUCING OPTICALLY ACTIVE Alpha-METHYLCYSTEINE DERIVATIVE
JP2005060311A (ja) * 2003-08-13 2005-03-10 Mochida Pharmaceut Co Ltd Ｎ−（ベンゾイル）アミノ酸誘導体を有効成分とするニューロパシー性疼痛治療剤
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
WO2005044780A1 (ja) 2003-11-10 2005-05-19 Kyorin Pharmaceutical Co., Ltd. アミノカルボン酸誘導体とその付加塩及びｓ１ｐ受容体調節剤
US20090215895A1 (en) * 2004-01-30 2009-08-27 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
GB0405289D0 (en) 2004-03-09 2004-04-21 Novartis Ag Organic compounds
CA2599662A1 (en) 2005-03-01 2006-09-08 Pfizer Limited Use of pde7 inhibitors for the treatment of neuropathic pain
TW200642687A (en) * 2005-03-01 2006-12-16 Pfizer Ltd Combinations comprising α-2-δ ligands
EA200701745A1 (ru) * 2005-03-17 2008-06-30 Пфайзер, Инк. Циклопропанкарбоксамидные производные
BRPI0609879A2 (pt) * 2005-04-28 2010-05-11 Pfizer Ltd derivados de aminoácidos
RS20080233A (sr) * 2005-12-02 2009-07-15 Pfizer Limited, Derivati spirocikličnog hinazolina kao inhibitori pde7

Also Published As

Publication number Publication date
KR20070116663A (ko) 2007-12-10
US7612226B2 (en) 2009-11-03
MX2007010978A (es) 2007-09-19
HK1116417A1 (en) 2008-12-24
IL185790A0 (en) 2008-01-06
WO2006114707A1 (en) 2006-11-02
JP4173909B1 (ja) 2008-10-29
CN101166524B (zh) 2010-12-22
CA2606353C (en) 2011-11-22
ZA200707678B (en) 2009-08-26
EP1879567A1 (en) 2008-01-23
NO20076000L (no) 2008-01-28
US20060247291A1 (en) 2006-11-02
KR100925900B1 (ko) 2009-11-09
PE20061435A1 (es) 2007-02-03
AU2006238933B2 (en) 2011-12-01
UY29498A1 (es) 2006-11-30
TNSN07400A1 (fr) 2009-03-17
BRPI0609879A2 (pt) 2010-05-11
CR9472A (es) 2007-12-04
JP2008539221A (ja) 2008-11-13
DOP2006000095A (es) 2006-10-15
SV2008002512A (es) 2008-02-08
AU2006238933A1 (en) 2006-11-02
GT200600178A (es) 2006-11-28
NL1031705C2 (nl) 2007-05-08
CN101166524A (zh) 2008-04-23
EA200701852A1 (ru) 2008-04-28
JP2009040767A (ja) 2009-02-26
MA29408B1 (fr) 2008-04-01
CA2606353A1 (en) 2006-11-02
TW200719889A (en) 2007-06-01
NL1031705A1 (nl) 2006-11-01
AP2007004161A0 (en) 2007-10-31

Similar Documents

Publication Publication Date Title
AR046660A1 (es) Metodo de tratamiento de la ateroesclerosis
AR033620A1 (es) Compuestos de sulfonilo de alfa-aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR084768A1 (es) Moduladores de la senda de complemento y usos de los mismos
AR077701A1 (es) Compuestos antiproliferativos, conjugados de los mismos, procedimientos para estos, y usos de los mismos
AR078944A1 (es) Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa
EA200501098A1 (ru) Антибактериальные агенты
AR035617A1 (es) Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios
CY1117085T1 (el) C7-φθορο υποκατεστημενες ενωσεις τετρακυκλινης
AR039154A1 (es) Aminoacidos con afinidad por la proteina alfa-2-delta
UY27636A1 (es) Compuesto inhibidor de la hepatitis c
AR045955A1 (es) Compuestos benzoimidazolicos
AR038843A1 (es) Derivados de fenetanolamina para el tratamiento de enfermedades respiratorias
AR035812A1 (es) Compuestos de acrilamida farmaceuticamente efectivos como inhibidores de la enoil-acp reductasa-fabi-; composiciones formuladas con dichos compuestos, metodo para inhibir dicha reductasa , respectivamente, para tratar infecciones bacterianas utilizando dichos compuestos y uso de los compuestos menci
AR040074A1 (es) Tiazolidinonas, su preparacion y su uso como medicamentos, e intermediarios para la preparacion de dichos compuestos
AR055283A1 (es) Inhibidores de cisteinproteasa de catepsina
AR054441A1 (es) Derivados de aminoacidos
AR051293A1 (es) Inhibidores bace
AR079130A1 (es) Compuestos inhibidores de la hepatitis c
PE20040666A1 (es) Derivados novedosos de piperidina
AR045979A1 (es) Amidas heterociclicas
PE20040907A1 (es) Derivados de anilinopirazol
AR045819A1 (es) Derivados de benzimidazol composiciones que los contienen, preparacion de los mismos y usos de los mismos
AR040570A1 (es) Deriados de acilaminotiazol, su preparacion y su aplicacion en terapeutica
BRPI0811245A2 (pt) Composto de carbamoilóxi-aril-alcanoil-aril-piperazinas, composições farmacêuticas que compreendem o composto, e método para tratar dor, ansiedade e depressão administrando o composto.
PE20020426A1 (es) ß-TIO-a-AMINOACIDOS, PROCEDIMIENTOS PARA SU PREPARACION Y MEDICAMENTOS QUE LOS CONTIENEN

Legal Events

Date Code Title Description
FA Abandonment or withdrawal